Stay updated with breaking news from Mark Bleackley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL), one of the first ASX-listed companies to make forays into cannabinoid and psychedelic therapeutic drugs,...
The trial assessed 3 doses of Incannex Healthcare Ltd's cannabinoid combination product IHL-42X at reducing AHI in obstructive sleep apnea.
Incannex Healthcare (ASX: IHL) has completed a preliminary analysis of data from a phase 2 proof-of-concept clinical trial investigating novel cannabinoid combination product IHL-42X for the treatment of obstructive sleep apnoea (OSA).
/PRNewswire/ -- Highlights: 20% of trial participants experienced a reduction in AHI of greater than 80% (range: 82.7% to 91.5%) during at least one treatment...
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has wrapped up preliminary analysis of data from its Phase 2 proof-of-concept clinical trial investigating...